Free Trial

GSK (GSK) Competitors

GSK logo
$43.92 +0.15 (+0.34%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$43.60 -0.31 (-0.71%)
As of 10/17/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK vs. NVS, AZN, NVO, SNY, ARGX, TAK, ONC, INSM, BNTX, and TEVA

Should you be buying GSK stock or one of its competitors? The main competitors of GSK include Novartis (NVS), AstraZeneca (AZN), Novo Nordisk A/S (NVO), Sanofi (SNY), argenex (ARGX), Takeda Pharmaceutical (TAK), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

GSK vs. Its Competitors

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

In the previous week, Novartis had 20 more articles in the media than GSK. MarketBeat recorded 25 mentions for Novartis and 5 mentions for GSK. Novartis' average media sentiment score of 1.38 beat GSK's score of 0.41 indicating that Novartis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GSK
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Novartis
20 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GSK has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

15.7% of GSK shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

GSK pays an annual dividend of $1.69 per share and has a dividend yield of 3.8%. Novartis pays an annual dividend of $2.59 per share and has a dividend yield of 2.0%. GSK pays out 78.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novartis pays out 37.7% of its earnings in the form of a dividend.

GSK presently has a consensus target price of $37.38, indicating a potential downside of 14.90%. Novartis has a consensus target price of $120.33, indicating a potential downside of 8.46%. Given Novartis' stronger consensus rating and higher probable upside, analysts plainly believe Novartis is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GSK
1 Sell rating(s)
7 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.88
Novartis
3 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.10

Novartis has a net margin of 25.64% compared to GSK's net margin of 10.81%. GSK's return on equity of 49.22% beat Novartis' return on equity.

Company Net Margins Return on Equity Return on Assets
GSK10.81% 49.22% 11.31%
Novartis 25.64%41.08%16.83%

Novartis has higher revenue and earnings than GSK. Novartis is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSK$31.63B2.82$3.29B$2.1620.33
Novartis$55.19B5.03$11.94B$6.8719.13

Summary

Novartis beats GSK on 14 of the 19 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Sign up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GSK vs. The Competition

MetricGSKMED IndustryMedical SectorNYSE Exchange
Market Cap$89.26B$3.44B$6.19B$21.83B
Dividend Yield3.86%2.28%5.70%3.62%
P/E Ratio20.3323.0185.5432.43
Price / Sales2.82486.53611.7860.31
Price / Cash7.8746.9237.1024.21
Price / Book5.4410.4112.234.59
Net Income$3.29B-$52.77M$3.33B$1.02B
7 Day Performance0.90%2.31%1.17%1.31%
1 Month Performance8.09%12.59%6.85%-0.93%
1 Year Performance13.92%11.18%58.93%9.51%

GSK Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GSK
GSK
1.8515 of 5 stars
$43.92
+0.3%
$37.38
-14.9%
+14.0%$89.26B$31.63B20.3368,629Dividend Cut
NVS
Novartis
2.5323 of 5 stars
$129.31
-0.6%
$120.33
-6.9%
+12.2%$273.16B$55.19B18.8275,883News Coverage
Positive News
AZN
AstraZeneca
3.1428 of 5 stars
$84.51
0.0%
$86.00
+1.8%
+8.2%$262.10B$56.50B31.7794,300Trending News
Analyst Downgrade
Short Interest ↓
Analyst Revision
NVO
Novo Nordisk A/S
4.3716 of 5 stars
$57.51
+1.0%
$77.50
+34.8%
-53.9%$256.76B$311.94B15.8077,349Trending News
Analyst Forecast
Gap Down
SNY
Sanofi
4.2075 of 5 stars
$48.80
+1.5%
$62.67
+28.4%
-7.8%$119.83B$44.46B11.7382,878Upcoming Earnings
ARGX
argenex
3.5861 of 5 stars
$799.56
+0.3%
$817.53
+2.2%
+49.3%$48.93B$3.05B41.001,599Analyst Revision
Gap Down
TAK
Takeda Pharmaceutical
3.3802 of 5 stars
$13.72
+0.0%
N/A-2.0%$43.64B$4.48T45.7247,455Analyst Forecast
ONC
BeOne Medicines
2.9541 of 5 stars
$327.03
+2.2%
$340.30
+4.1%
N/A$35.84B$3.81B-189.0311,000
INSM
Insmed
2.9311 of 5 stars
$163.94
+1.0%
$149.06
-9.1%
+122.4%$34.65B$363.71M-28.711,271News Coverage
Positive News
Analyst Forecast
BNTX
BioNTech
2.6519 of 5 stars
$102.30
+0.2%
$134.32
+31.3%
-5.9%$24.59B$2.88B-63.946,772Analyst Forecast
TEVA
Teva Pharmaceutical Industries
3.5883 of 5 stars
$20.02
-0.1%
$25.57
+27.8%
+7.7%$22.96B$16.63B-125.0936,830

Related Companies and Tools


This page (NYSE:GSK) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners